This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Casein kinase 1 α (CSNK1A; CKI- α)	<p>Mouse and cell culture studies suggest inhibiting CKI-α could help treat AML. In a mouse model of AML, shRNA against Cki-α decreased leukemic cell growth and increased survival compared with control shRNA. In irradiated mice, transplantation of a mixture of human AML and normal hematopoietic stem cells that had been pretreated with a small molecule CKI-α inhibitor resulted in decreased leukemic growth compared with transplantation of cells pretreated with vehicle and did not impair normal hematopoiesis. Next steps could include testing additional CKI-α inhibitors in animal AML models.</p> <p>SciBX 7(15); doi:10.1038/scibx.2014.422 Published online April 17, 2014</p>	Patent and licensing status unavailable	<p>Järås, M. <i>et al. J. Exp. Med.</i>; published online March 10, 2014; doi:10.1084/jem.20131033 Contact: Benjamin L. Ebert, Harvard Medical School, Boston, Mass. e-mail: bebert@partners.org</p>